FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386784480> ?p ?o ?g. }

• W4386784480 endingPage "003" @default.
• W4386784480 startingPage "PO" @default.
• W4386784480 abstract "Abstract Introduction: Pembrolizumab monotherapy and pembrolizumab plus platinum-based chemotherapy are the standard of care for first-line treatment of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Pembrolizumab plus lenvatinib showed promising antitumor activity and manageable safety in metastatic HNSCC in the phase 1b/2 Study 111/KEYNOTE-146 trial. The randomized, open-label, phase 2 LEAP-009 (NCT04428151) study is designed to evaluate the safety and efficacy of lenvatinib plus pembrolizumab or lenvatinib monotherapy versus chemotherapy in R/M HNSCC upon progression after treatment with platinum-based therapy and a PD-1/L1 inhibitor. Materials and Methods: Eligible patients have locally incurable, histologically confirmed R/M HNSCC (of the oral cavity, oropharynx, hypopharynx, and/or larynx), ECOG PS of 0 or 1, no ulceration and/or fungation of disease on skin, and disease progression on or after platinum-based therapy (with/without cetuximab) and PD-1/L1 inhibitor (progression must be within 12 weeks from last dose and patients must have received ≥2 doses). Patients will be randomly assigned 3:3:2 to receive oral lenvatinib 20 mg every day plus pembrolizumab 200 mg IV every 3 weeks (≤35 pembrolizumab cycles), standard-of-care chemotherapy (investigator’s choice of docetaxel, paclitaxel, cetuximab, or capecitabine), or oral lenvatinib monotherapy 24 mg every day. Treatment will continue until centrally verified disease progression, unacceptable toxicity, or withdrawal. Patients who experience centrally verified disease progression in chemotherapy or lenvatinib monotherapy arms may cross over to lenvatinib plus pembrolizumab at time of disease progression with sponsor consultation. Randomization will be stratified by PD-L1 tumor proportion score (&lt;50% vs ≥50%) and ECOG PS (0 vs 1). Imaging will be performed every 6 weeks through year 1 and every 9 weeks thereafter. Response will be assessed per RECIST v1.1 by blinded independent central review. Safety will be monitored throughout the study and for 30 days following treatment end (90 days for serious AEs) and graded per NCI CTCAE v5.0. The primary end point is objective response rate and secondary end points are progression-free survival, duration of response, overall survival, and safety. Results: Planned enrollment is approximately 400, and recruitment is currently underway in Asia, Australia, Europe, and North America. Conclusion: Results of LEAP-009 will provide clarity on the efficacy and safety of lenvatinib with or without pembrolizumab versus chemotherapy for patients with R/M HNSCC upon progression after platinum and immunotherapy. Citation Format: Kevin J. Harrington, Hye Ryun Kim, Sebastien Salas, Marc Oliva, Robert Metcalf, Mogens Bernsdorf, Ji-Won Kim, Ezra E. W. Cohen, Lillian Siu, Danny Rischin, Lisa Licitra, Jan Vermorken, Quynh Le, Makoto Tahara, Jean-Pascal Machiels, Karen O'Hara, Kumudu Pathiraja, Burak Gumuscu, Behzad Bidadi, Barbara Burtness. Lenvatinib with or without pembrolizumab versus chemotherapy for treatment of recurrent or metastatic head and neck squamous cell carcinoma that progressed on platinum therapy and immunotherapy: Phase 2 LEAP-009 [abstract]. In: Proceedings of the AACR-AHNS Head and Neck Cancer Conference: Innovating through Basic, Clinical, and Translational Research; 2023 Jul 7-8; Montreal, QC, Canada. Philadelphia (PA): AACR; Clin Cancer Res 2023;29(18_Suppl):Abstract nr PO-003." @default.
• W4386784480 created "2023-09-16" @default.
• W4386784480 creator A5000204204 @default.
• W4386784480 creator A5006291712 @default.
• W4386784480 creator A5007067879 @default.
• W4386784480 creator A5011675274 @default.
• W4386784480 creator A5013860869 @default.
• W4386784480 creator A5023000705 @default.
• W4386784480 creator A5029098443 @default.
• W4386784480 creator A5029309849 @default.
• W4386784480 creator A5039442937 @default.
• W4386784480 creator A5044844420 @default.
• W4386784480 creator A5045172802 @default.
• W4386784480 creator A5047193688 @default.
• W4386784480 creator A5054273718 @default.
• W4386784480 creator A5054682698 @default.
• W4386784480 creator A5059172426 @default.
• W4386784480 creator A5060469120 @default.
• W4386784480 creator A5066800365 @default.
• W4386784480 creator A5067324005 @default.
• W4386784480 creator A5088734038 @default.
• W4386784480 creator A5091554389 @default.
• W4386784480 date "2023-09-15" @default.
• W4386784480 modified "2023-10-03" @default.
• W4386784480 title "Abstract PO-003: Lenvatinib with or without pembrolizumab versus chemotherapy for treatment of recurrent or metastatic head and neck squamous cell carcinoma that progressed on platinum therapy and immunotherapy: Phase 2 LEAP-009" @default.
• W4386784480 doi "https://doi.org/10.1158/1557-3265.aacrahns23-po-003" @default.
• W4386784480 hasPublicationYear "2023" @default.
• W4386784480 type Work @default.
• W4386784480 citedByCount "0" @default.
• W4386784480 crossrefType "journal-article" @default.
• W4386784480 hasAuthorship W4386784480A5000204204 @default.
• W4386784480 hasAuthorship W4386784480A5006291712 @default.
• W4386784480 hasAuthorship W4386784480A5007067879 @default.
• W4386784480 hasAuthorship W4386784480A5011675274 @default.
• W4386784480 hasAuthorship W4386784480A5013860869 @default.
• W4386784480 hasAuthorship W4386784480A5023000705 @default.
• W4386784480 hasAuthorship W4386784480A5029098443 @default.
• W4386784480 hasAuthorship W4386784480A5029309849 @default.
• W4386784480 hasAuthorship W4386784480A5039442937 @default.
• W4386784480 hasAuthorship W4386784480A5044844420 @default.
• W4386784480 hasAuthorship W4386784480A5045172802 @default.
• W4386784480 hasAuthorship W4386784480A5047193688 @default.
• W4386784480 hasAuthorship W4386784480A5054273718 @default.
• W4386784480 hasAuthorship W4386784480A5054682698 @default.
• W4386784480 hasAuthorship W4386784480A5059172426 @default.
• W4386784480 hasAuthorship W4386784480A5060469120 @default.
• W4386784480 hasAuthorship W4386784480A5066800365 @default.
• W4386784480 hasAuthorship W4386784480A5067324005 @default.
• W4386784480 hasAuthorship W4386784480A5088734038 @default.
• W4386784480 hasAuthorship W4386784480A5091554389 @default.
• W4386784480 hasConcept C121608353 @default.
• W4386784480 hasConcept C126322002 @default.
• W4386784480 hasConcept C143998085 @default.
• W4386784480 hasConcept C2776264508 @default.
• W4386784480 hasConcept C2776530083 @default.
• W4386784480 hasConcept C2776694085 @default.
• W4386784480 hasConcept C2776833033 @default.
• W4386784480 hasConcept C2777701055 @default.
• W4386784480 hasConcept C2779761222 @default.
• W4386784480 hasConcept C2779998722 @default.
• W4386784480 hasConcept C2780057760 @default.
• W4386784480 hasConcept C2781190966 @default.
• W4386784480 hasConcept C509974204 @default.
• W4386784480 hasConcept C526805850 @default.
• W4386784480 hasConcept C71924100 @default.
• W4386784480 hasConceptScore W4386784480C121608353 @default.
• W4386784480 hasConceptScore W4386784480C126322002 @default.
• W4386784480 hasConceptScore W4386784480C143998085 @default.
• W4386784480 hasConceptScore W4386784480C2776264508 @default.
• W4386784480 hasConceptScore W4386784480C2776530083 @default.
• W4386784480 hasConceptScore W4386784480C2776694085 @default.
• W4386784480 hasConceptScore W4386784480C2776833033 @default.
• W4386784480 hasConceptScore W4386784480C2777701055 @default.
• W4386784480 hasConceptScore W4386784480C2779761222 @default.
• W4386784480 hasConceptScore W4386784480C2779998722 @default.
• W4386784480 hasConceptScore W4386784480C2780057760 @default.
• W4386784480 hasConceptScore W4386784480C2781190966 @default.
• W4386784480 hasConceptScore W4386784480C509974204 @default.
• W4386784480 hasConceptScore W4386784480C526805850 @default.
• W4386784480 hasConceptScore W4386784480C71924100 @default.
• W4386784480 hasIssue "18_Supplement" @default.
• W4386784480 hasLocation W43867844801 @default.
• W4386784480 hasOpenAccess W4386784480 @default.
• W4386784480 hasPrimaryLocation W43867844801 @default.
• W4386784480 hasRelatedWork W1996158748 @default.
• W4386784480 hasRelatedWork W2401063966 @default.
• W4386784480 hasRelatedWork W2986633517 @default.
• W4386784480 hasRelatedWork W3012537123 @default.
• W4386784480 hasRelatedWork W4224739813 @default.
• W4386784480 hasRelatedWork W4254273398 @default.
• W4386784480 hasRelatedWork W4256037973 @default.
• W4386784480 hasRelatedWork W4323657820 @default.
• W4386784480 hasRelatedWork W4361014962 @default.
• W4386784480 hasRelatedWork W4380151361 @default.
• W4386784480 hasVolume "29" @default.
• W4386784480 isParatext "false" @default.
• W4386784480 isRetracted "false" @default.
• W4386784480 workType "article" @default.